Advertisement

Advertisement

Lung Cancer

Phase II Study of Trilaciclib in Pretreated Patients With Metastatic NSCLC Initiated

PRESERVE 4 (ClinicalTrials.gov identifier: NCT04863248)—a multicenter, randomized, double-blind, placebo-controlled phase II study of trilaciclib administered prior to docetaxel in patients with metastatic non–small cell lung cancer (NSCLC) in the second- and third-line setting who have previously...

Lung Cancer
Genomics/Genetics

ASCO and Ontario Health Publish Joint Update on Guideline for Targeted Therapy in NSCLC With Driver Alterations

ASCO and Ontario Health (Cancer Care Ontario) have jointly published an update1 to the 2017 ASCO guideline2 regarding systemic therapy recommendations for stage IV non–small cell lung cancer (NSCLC) with driver alterations. Guideline Co-Chair Nasser H. Hanna, MD, of the Indiana University Simon...

Lung Cancer
Immunotherapy

Cemiplimab-rwlc for First-Line Treatment of NSCLC With High PD-L1 Expression

On February 22, 2021, cemiplimab-rwlc was approved for first-line treatment of patients with advanced non–small cell lung cancer (NSCLC; locally advanced who are not candidates for surgical resection or definitive chemoradiation therapy or metastatic) whose tumors have high PD-L1 expression (tumor...

Lung Cancer
Immunotherapy

Expert Point of View: Jhanelle E. Gray, MD

Formal discussant of the CheckMate 816 trial, Jhanelle E. Gray, MD, of Moffitt Cancer Center, Tampa, said that both neoadjuvant and adjuvant therapies have been shown to improve overall survival and relapse-free survival in non–small cell lung cancer (NSCLC). “Overall, neoadjuvant outcomes compare...

Lung Cancer
Immunotherapy

CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response in Resectable NSCLC

Neoadjuvant chemotherapy with nivolumab plus platinum-doublet chemotherapy significantly improved pathologic complete response rates compared with chemotherapy alone in patients with resectable stage IB to IIIA non–small cell lung cancer (NSCLC), according to the results of the CheckMate 816 study...

Lung Cancer
Issues in Oncology

Accuracy of Lung Cancer Risk Model in Diverse Populations

A commonly used risk prediction model does not accurately identify high-risk Black patients with lung cancer who could gain life-saving benefit from early screening—paving the way for improving screenings and guidelines. These findings were published in a research letter by Shusted et al in JAMA...

Bladder Cancer
Lung Cancer
Immunotherapy

FDA Pipeline: Priority Reviews of Treatments for Bladder and Lung Cancers

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review designation to treatments for surgically resected, high-risk, muscle-invasive urothelial carcinoma and epidermal growth factor receptor exon 20 insertion mutation–positive metastatic non–small cell lung cancer (NSCLC)....

Immunotherapy
Lung Cancer
Genomics/Genetics

First-Line Immune Checkpoint Inhibitor Monotherapy vs Chemoimmunotherapy in Advanced NSCLC According to KRAS Variant Status

In a study reported in a research letter in JAMA Oncology, Sun et al found that first-line immune checkpoint inhibitor monotherapy was associated with better overall survival among patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50% and KRAS variant vs KRAS...

Lung Cancer
Immunotherapy

Five-Year Efficacy Outcomes With Pembrolizumab vs Chemotherapy in Metastatic NSCLC With PD-L1 Tumor Proportion Score of at Least 50%

As reported by Martin Reck, MD, PhD, and colleagues in the Journal of Clinical Oncology, the 5-year follow-up of the pivotal phase III KEYNOTE-024 trial shows maintained overall survival benefit in patients treated with pembrolizumab vs chemotherapy—despite substantial crossover to the...

Lung Cancer
Symptom Management

Contralateral Esophagus-Sparing Radiotherapy Technique Reduces Rates of Esophagitis in Patients With Lung Cancer Receiving High-Dose Chemoradiation

In a small, single-institution phase I trial reported in JAMA Oncology, Kamran et al found that the use of a contralateral esophagus-sparing radiotherapy technique in patients receiving high-dose chemoradiation for locally advanced lung cancer was associated with no cases of grade ≥ 3 esophagitis,...

Breast Cancer
Lung Cancer
Prostate Cancer

Safety of Stereotactic Body Radiotherapy for Patients With Multiple Metastases

In the phase I NRG-BR001 trial reported in JAMA Oncology, Chmura et al found that stereotactic body radiotherapy (SBRT) could be used safely to treat multiple metastases in patients with breast, lung, and prostate cancers.   Study Details The trial was conducted within a consortium of North...

Gynecologic Cancers
Lung Cancer
Issues in Oncology

Transmission of Cancer to Infants From Mothers With Cervical Cancer During Vaginal Delivery

In a brief report in The New ­England Journal of Medicine, Ayumu Arakawa, MD, of the Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, and colleagues described identification of lung cancer in two boys that likely resulted from transmission of maternal cervical cancer tumor...

Lung Cancer

Nivolumab/Ipilimumab Plus Two Cycles of Histology-Based Chemotherapy: Another Option in First-Line Metastatic NSCLC

Introduction of immunotherapy has revealed a paradigm shift in the management of patients with metastatic non–small cell lung cancer (NSCLC) that does not harbor a therapeutically targetable driver mutation. Over the past 5 years, several trials have informed treatment decisions, based on disease...

Lung Cancer

First-Line Nivolumab/Ipilimumab Plus Chemotherapy Improves Overall Survival vs Chemotherapy in Stage IV or Recurrent NSCLC

As reported in The Lancet Oncology by Luis Paz-Ares, MD, of the Universidad Complutense & CiberOnc, Madrid, and colleagues, the phase III CheckMate 9LA trial has shown improved overall survival with first-line nivolumab/ipilimumab plus two cycles of chemotherapy vs four cycles of chemotherapy...

Genomics/Genetics
Lung Cancer

Patient Knowledge and Expectations Regarding Genomic Testing Results

As reported in JCO Oncology Practice by Roth et al, many participants in a biomarker-driven master protocol trial (Lung Cancer Master Protocol [Lung-MAP]; SWOG S1400GEN) did not display correct knowledge or expectations about using the results of genomic testing. Study Details Lung-MAP is a...

Lung Cancer
Immunotherapy

First-Line Tislelizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Squamous NSCLC

In the Chinese phase III RATIONALE 307 trial reported in JAMA Oncology, Wang et al found that tislelizumab plus chemotherapy significantly prolonged progression-free survival vs chemotherapy alone in the first-line treatment of patients with advanced squamous non–small cell lung cancer (NSCLC). As...

Pancreatic Cancer
Hepatobiliary Cancer
Colorectal Cancer
Breast Cancer
Skin Cancer
Lung Cancer
Prostate Cancer
Issues in Oncology

Estimated Shifts in Cancer Incidence and Death Over Next 2 Decades

In the next 2 decades, rankings of incidence and death across cancer types in the United States will undergo important changes, according to new research published by Lola Rahib, PhD, and colleagues in JAMA Network Open. The study estimates that pancreatic cancer is on course to become the...

Lung Cancer
Immunotherapy

Cancer Aneuploidy May Predict Response to Immunotherapy in Patients With NSCLC

Lower levels of cancer aneuploidy were associated with more favorable outcomes after immune checkpoint inhibition in patients with non–small cell lung cancer (NSCLC), according to data presented by Alessi et al at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021...

lung cancer
immunotherapy

Patrick M. Forde, MD, on NSCLC: Nivolumab and Chemotherapy as Neoadjuvant Treatment

Patrick M. Forde, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, discusses results from the CheckMate 816 trial, which showed that adding nivolumab to chemotherapy as a neoadjuvant treatment for patients with resectable non–small cell lung cancer improved the pathologic complete response rate to 24%, compared to 2.2% with chemotherapy alone (Abstract CT003).

Lung Cancer
Immunotherapy

Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response Rate for Patients With Resectable NSCLC

Neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathologic complete response (pCR) rates compared with chemotherapy alone in patients with resectable stage IB to IIIA non–small cell lung cancer (NSCLC), according to results of the randomized, phase III, open-label...

Lung Cancer
Genomics/Genetics

Expert Point of View: Gillianne G.Y. Lai, MBBS

Gillianne G.Y. Lai, MBBS, of the National Cancer Centre, Singapore, discussed the presentations on novel agents for exon 20 insertion mutations in non–small cell lung cancer (NSCLC), which account for about one-third of tyrosine kinase resistance mutations. Although tyrosine kinase mutations are...

Lung Cancer
Genomics/Genetics

Lung Cancers With Rare EGFR Mutations Being Tackled by Novel Agents

Next-generation inhibitors of epidermal growth factor receptor (EGFR) exon 20 insertion mutations showed promise in patients with advanced non–small cell lung cancer (NSCLC) in early-phase trials presented during the International Association Society for Lung Cancer 2020 World Conference on Lung...

Lung Cancer
Genomics/Genetics

Patients With NSCLC and Driver Mutations May Be More Likely to Present With Brain Metastasis at Diagnosis

The incidence of brain metastasis at diagnosis in patients with non–small cell lung cancer (NSCLC) harboring driver mutations was high, according to findings presented by Rashkit et al at the European Lung Cancer Virtual Congress 2021 (Abstract 38P). However, these patients achieved treatment...

Issues in Oncology
Lung Cancer

Detection of Emphysema Among Patients With or Without Prior COPD Diagnosis Undergoing Low-Dose CT Screening for Lung Cancer

In a prospective cohort study reported in Clinical Imaging, researchers in the International Early Lung Cancer Action Program (I-ELCAP) identified emphysema in nearly one-quarter of patients undergoing baseline low-dose computed tomography (CT) screening for lung cancer. Three-quarters of those...

Lung Cancer

Lymph Node Collection Kit May Help Improve Outcomes After Lung Cancer Surgery

A lymph node collection kit may help surgeons attain complete resection and improve long-term survival after curative-intent lung cancer surgery, according to a recent study published by Matthew Smeltzer, PhD, and colleagues in JTO Clinical and Research Reports. Surgical resection is the most...

Lung Cancer
Genomics/Genetics

Analysis Identifies Frequency of PI3K Pathway Alterations in Patients With NSCLC

A retrospective analysis of patients with non–small cell lung cancer (NSCLC) identified potentially targetable alterations in the PI3K pathway that were not mutually exclusive to mutations in other pathways, according to findings presented by Lage et al during the European Lung Cancer Virtual...

Lung Cancer
COVID-19

Incidence of Brain Metastases in Patients Diagnosed With Stage IV NSCLC During the COVID-19 Pandemic

Computed tomography and/or magnetic resonance imaging demonstrated that 39% of patients diagnosed with stage IV non–small cell lung cancer (NSCLC) presented with de novo brain metastases during the COVID-19 pandemic. This percentage was higher than the historic rate of 25%, and many of these...

Lung Cancer
Issues in Oncology

Some Patients With Lung Cancer Report Feeling Uninformed About Their Disease, Uninvolved With Their Treatment

More than 1 in 10 patients with lung cancer do not know what type of tumor they have, according to data from a 17-country study carried out by the Global Lung Cancer Coalition (GLCC) presented by Beattie et al at the European Lung Cancer Virtual Congress 2021 (Abstract 209P_PR). Nearly one in five...

Lung Cancer
Genomics/Genetics

Adagrasib for Patients With Advanced KRAS G12C–Mutated NSCLC

Treatment with the KRAS G12C inhibitor adagrasib showed clinical activity in patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, confirming its role as a therapeutic target. Results from the KRYSTAL-1 trial were reported at the European Lung Cancer Virtual...

Lung Cancer

ASCO Publishes Guideline Endorsement of ASTRO Guideline for Radiation Therapy in SCLC

An ASCO Expert Panel has endorsed an American Society for Radiation Oncology (ASTRO) guideline on radiation therapy for small cell lung cancer (SCLC), stating the recommendations in the ASTRO guideline “are clear, thorough, and based upon the most relevant scientific evidence” available.1...

Breast Cancer
Lung Cancer
Global Cancer Care

Female Breast Cancer Surpasses Lung Cancer as the Most Commonly Diagnosed Cancer Worldwide

Cancer ranks as a leading cause of death in every country in the world, and, for the first time, female breast cancer is the most commonly diagnosed cancer, overtaking lung cancer, according to a collaborative report from the American Cancer Society (ACS) and the International Agency for Research...

Lung Cancer
Immunotherapy

Next Up in NSCLC: Antibody-Drug Conjugates

Antibody-drug conjugates directed against HER2, HER3, and trophoblast cell-surface antigen 2 (TROP2) are showing encouraging antitumor activity in advanced non–small cell lung cancer (NSCLC), according to research presented during the virtual edition of the International Association for the Study...

Lung Cancer

ITACA Trial: No Survival Benefit for Tailoring Adjuvant Chemotherapy in NSCLC

Tailoring adjuvant chemotherapy based on the expression of two molecular markers did not lead to a survival advantage in patients with completely resected stage II to III non–small cell lung cancer (NSCLC) in the phase III ITACA trial. This result was presented during the virtual edition of the...

Lung Cancer
Immunotherapy

Immunotherapy Doublet as Maintenance Therapy for Extensive-Disease SCLC

As reported in the Journal of Clinical Oncology by Taofeek K. Owonikoko, MD, PhD, and colleagues, the phase III CheckMate 451 trial showed no improvement in overall survival with combined nivolumab and ipilimumab vs placebo as maintenance therapy for extensive-disease small cell lung cancer. Study ...

Kidney Cancer
Lung Cancer

FDA Pipeline: Priority Review for Kidney Cancer Treatment, Fast Track Designation for NSCLC Treatment

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to the HIF-2α inhibitor belzutifan for the treatment of patients with von Hippel-Lindau (VHL) disease–associated renal cell carcinoma. The agency also granted Fast Track designation to poziotinib for the treatment of...

Lung Cancer

Updated Evidence Report and Systematic Review of Low-Dose CT Screening for Lung Cancer

In an analysis of updated evidence on low-dose computed tomography (CT) screening for lung cancer reported in JAMA, Jonas et al found that screening can reduce lung cancer mortality but may be associated with a range of potential harms. The analysis was performed to inform the new U.S. Preventive...

Lung Cancer

High- vs Standard-Dose Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer

In a phase II trial reported in The Lancet Oncology, Grønberg et al found that use of high-dose vs standard-dose twice daily thoracic radiotherapy as part of first-line chemoradiotherapy was associated with significantly improved overall survival and similar toxicity in patients with limited-stage...

Breast Cancer
Bladder Cancer
Gastrointestinal Cancer
Hepatobiliary Cancer
Lung Cancer
Immunotherapy

FDA Oncologic Drugs Advisory Committee to Review Status of Six Indications Granted Accelerated Approval

Recently, the U.S. Food and Drug Administration (FDA) announced that the agency will hold a public meeting of the Oncologic Drugs Advisory Committee on April 27 to 29 to discuss six indications granted accelerated approval that have since reported results from confirmatory trials that have not...

Lung Cancer
Immunotherapy

Expert Point of View: Roy S. Herbst, MD, PhD, FACP, FASCO, and Shinichi Toyooka, MD

The ASCO Post reached out to Roy S. Herbst, MD, PhD, FACP, FASCO, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, New Haven, for his thoughts on the LCMC3 trial of neoadjuvant atezolizumab.1 Dr. Herbst led...

Lung Cancer
Immunotherapy

Neoadjuvant Atezolizumab in Lung Cancer: LCMC3 Trial Meets Primary Endpoint

Neoadjuvant treatment with single-agent atezolizumab in patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and a pathologic complete response rate of 7%, in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study.1 The findings were...

Lung Cancer
Immunotherapy

Expert Point of View: Rina Hui, MBBS, PhD, and Melina Marmarelis, MD

“It has been a long time coming to see a positive randomized phase III study with a checkpoint inhibitor in relapsed mesothelioma,” said the study’s invited discussant, Rina Hui, MBBS, PhD, Clinical Professor of Medicine, Crown Princess Mary Cancer Centre, Westmead Hospital, University of Sydney,...

Lung Cancer
Immunotherapy

CONFIRM Trial Reports Improvement in Survival With Nivolumab in Relapsed Malignant Mesothelioma

For the first time, a treatment has been shown to improve overall survival in heavily pretreated patients with relapsed malignant mesothelioma. In the phase III CONFIRM trial, single-agent nivolumab led to a significant improvement in both overall and progression-free survival, according to...

Lung Cancer

Tepotinib for Metastatic NSCLC With MET Exon 14–Skipping Alterations

On February 3, 2021, tepotinib was granted accelerated approval for treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations.1,2 Supporting Efficacy Data Approval was supported by findings from the...

lung cancer
covid-19

Fred R. Hirsch, MD, PhD, on Searching for Therapeutic Strategies for Patients With Lung Cancer and COVID-19 Infection

Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, invites his colleagues to enroll their patients in a large prospective study, for which he serves as Principal Investigator. The study is searching for solutions for treating patients with lung cancer who also have the coronavirus, because so many experience an aggressive course of infection.

Lung Cancer

Continued Survival Benefit With Durvalumab Plus Chemotherapy vs Chemotherapy Alone in Extensive-Stage SCLC

As reported in The Lancet Oncology by Jonathan W. Goldman, MD, of the David Geffen School of Medicine at University of California Los Angeles, and colleagues, updated results from the phase III CASPIAN trial show maintained improvement in overall survival with first-line durvalumab plus...

Lung Cancer

USPSTF Issues Final Recommendation Statement on Screening for Lung Cancer

Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for lung cancer in people who do not have signs or symptoms. Based on the evidence, the USPSTF recommends yearly screening using a low-dose computed tomography (CT) scan for people aged...

Lung Cancer

Updated Analysis of Outcomes With Entrectinib for Advanced ROS1 Fusion–Positive NSCLC

As reported in the Journal of Clinical Oncology by Rafal Dziadziuszko, MD, and colleagues, an updated integrated analysis of three phase I or II trials of entrectinib in patients with advanced ROS1-positive non–small cell lung cancer (NSCLC) indicated that treatment continues to be associated with...

lung cancer
immunotherapy

Hossein Borghaei, DO, on Bispecific T-Cell–Engager Immune Therapy for Small Cell Lung Cancer

Hossein Borghaei, DO, of Fox Chase Cancer Center, discusses phase I results from a study of AMG 757, an experimental bispecific T-cell–engager (BiTE) immune therapy aimed at the DLL3 molecular target in patients with small cell lung cancer. At this early stage, results show clinical efficacy and safety, with 37% of 51 evaluable patients exhibiting disease control (Abstract OA11.03).

Lung Cancer

FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC

On March 3, the U.S. Food and Drug Administration (FDA) granted regular approval to lorlatinib (Lorbrena) for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. The FDA also approved the...

Lung Cancer

Study Examines Extrapleural Pneumonectomy After IMRT for Malignant Pleural Mesothelioma

In a Canadian single-center phase II feasibility study reported in The Lancet Oncology, Cho et al found that a treatment protocol (surgery for mesothelioma after radiotherapy, also known as SMART) consisting of hemithoracic intensity-modulated radiotherapy (IMRT) followed by extrapleural...

Advertisement

Advertisement

Advertisement